Introduction {#Sec1}
============

Overweight and obesity have been a worldwide epidemic and led to a rise in the insulin resistance-related morbidities, progression to type 2 diabetes and increasing risk of cardiovascular disease^[@CR1],[@CR2]^. It is difficult to achieve or maintain weight loss for many people and we have proposed dietary strategies based on reducing the absorptivity or amount of glucose in the diet to improve metabolic health, rather than depending on weight loss^[@CR3]^. Resistant starch, as a dietary ingredient, can slow digestion, reduce abdominal fat^[@CR4]--[@CR6]^ and cholesterol^[@CR7]^ in rodents and human. RS increases systemic insulin sensitivity and significantly reduces adipose tissue decomposition, which has clinical significance in the care and prevention of diabetes^[@CR8]^. Although an association between RS supplementation and insulin concentrations, insulin sensitivity, and lipid parameters is biologically credible, the results of epidemiological studies on this relationship are inconsistent.

Many studies from different countries have been published to report the effects of RS about glucose, insulin, insulin resistance and sensitivity, and lipid parameters, however, no systematic analysis on this issue is still reported so far. Therefore, a meta-analysis was performed to sum up the existing evidence about this topic.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

We performed a search of PubMed and Medline databases. The final search was conducted in October 2018 and combinations of search terms were included (resistant starch or RS) and (blood glucose or plasma insulin or insulin resistance or insulin sensitivity or cholesterol or triglyceride or LDL or HDL or hyperlipidemia or triacylglycerol or dyslipidemia) and (overweight or obesity). The reference lists of each papers were scanned by us to identify additional studies. If necessary, we try to contact the author for more information.

Selection criteria {#Sec4}
------------------

Studies were included if they met the following criteria, which included clinical trials; controlled; Intervention of obesity or overweight (BMI ≥ 25) with resistant starch; with adults (\>18 years old); baseline characteristic without difference; without acute effect of RS; assessing fasting glucose or fasting insulin or plasma lipid or insulin sensitivity or insulin resistance as outcomes; with data of the related outcomes or data necessary to calculate them. For potentially qualified articles that are with unclear information, we contacted the correspondence author via email and asked for more explanations. The articles were included only if the problem has been solved and met the selection criteria. No duplicate or triplicate clauses are included.

Data extraction {#Sec5}
---------------

All data were extracted independently and cross-checked by three reviewers (Y.W., J.C., and X.T.W.) according to the selection criteria. Articles would be discussed again in case of divergent opinions. The following information were extracted: patient characteristics (gender, age, and BMI), sample size, resistant starch or placebo components, dosage, duration of treatment and result (mean and standard deviation after supplement). Outcomes included plasma lipid (total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and triglycerides), insulin sensitivity, insulin resistance, B-cell function, fasting insulin and glucose. For studies that do not give the average and standard deviation values of any relevant results, we contacted the correspondence authors to require these values, and we included the articles that can offer these data.

Quality assessment {#Sec6}
------------------

Quality assessment was performed according to the quality assessment toll for quantitative studies, Effect public health practice project (EPHPP)^[@CR9]^. The EPHPP toll include six evaluation criteria: selection bias, study design, confounding factors, blind method, data collection methods and withdrawals, and dropouts. According to the characteristics of each criterion reported in the study, the six criteria were rated as "strong", "moderate" or "weak". Once the standard scores are aggregated, each study will receive an overall assessment of strong, moderate or weak quality. In order for a study to be rated as "strong", four of the six quality assessment criteria must be rated as strong without weak ratings. if less than four criteria were rated as strong and one criterion was as weak, it achieved a rating of "moderate"^[@CR9]^.

Statistical analysis {#Sec7}
--------------------

We performed all statistical analyses with Statistical Software-STATA, version 12.0. Mean differences (MD) between intervention (RS) and control group for each of the above results were summarized using the random-effect model, which was applied to the meta-analyses when the studies were clinically heterogeneous. The values of mean change from baseline standard deviations were used to calculate missing standard deviations. When some trials report the low and high end or 25th to 75th percentiles of the range, the standard deviation was regarded as the formula range/4^[@CR10]^.

Studies with resistant starch were divided into two groups (nondiabetic and diabetic), because of different composition of gut microbiota between the two populations^[@CR11],[@CR12]^, and due to high concentrations of insulin and glucose in the diabetic population, which may produce more significant results through interventions. We used the *Q* and *I*^2^ statistics to test statistical heterogeneity among studies^[@CR13]^. we considered *P* value of less than 0.1 as a statistically significant heterogeneity for the *Q* statistic. If a study has a heterogeneous source, it was excluded of the analysis. Data synthesis of these heterogeneous studies was presented in a narrative analysis. the Egger weighted regression method was used to assess publication bias^[@CR14]^; which considered *P* value of less than 0.1 as a statistically significant publication bias.

Results {#Sec8}
=======

Search results {#Sec9}
--------------

There were 2212 articles identified in the search, the titles and abstracts of the articles were screened. Only 27 articles were considered eligible. After review of full text articles, 13/27 met the inclusion and were eligible in this meta-analysis. Figure [1](#Fig1){ref-type="fig"} showed the selection process.Fig. 1Screening and selection process of studies

Baseline characteristics {#Sec10}
------------------------

The thirteen included studies^[@CR15]--[@CR27]^ were published between 2004 and 2018. The Table [1](#Tab1){ref-type="table"} showed the characteristics of these studies. Of all the studies. three of them were from Europe^[@CR16],[@CR19],[@CR24]^; seven from America^[@CR15],[@CR17],[@CR18],[@CR22],[@CR23],[@CR25],[@CR27]^; two from Middle East^[@CR20],[@CR21]^; and one from Asia^[@CR26]^. Of the thirteen trials, five of them were randomized, crossover study, the other eight were randomized controlled trials. Sample sizes were 12--60 cases and follow-up ranged from 2 to 12 weeks. The doses of RS ranged from 10 to 45 g per day. The effect of taking resistant starch versus placebo on glycemic status, insulin and lipid profile are described in Table [2](#Tab2){ref-type="table"}. There are three studies^[@CR18],[@CR23],[@CR27]^, including four or two groups, respectively in their analysis and all were included for the meta-analysis. There was only one study in diabetic or nondiabetic group for some parameters such as HOMA%B, HbA1c, HOMA%S, HOMA-IR, and LDL-c so we did not make stratified analysis for these parameters.Table 1Characteristics of included studiesStudy (year)CountrySupplementStudy designPopulationSexBMI placebo vs. controlAge (years) placebo vs. controlSample sizeIntervention (RS dose, g)Control (RS dose, g)DurationResultsPark OJ (2004)KoreaRSPlacebo-controlstudyOverweight and obese subjectsF26.6 ± 0.7vs.27.9 ± 0.542.3 ± 3.1vs.43.6 ± 2.825Resistant starch(40)Corn starch(0)3 weeks↓fasting glucose↓fasting insulin↓TC↑TG↓HDL-c↓LDL-cCastillo JL (2010)MexicoNBSCrossover studyObese adults with type 2 diabeteMF34.89 ± 2.3251.7 ± 5.630NBS(24)Soy milk(0)4 weeks↓Fasting glycemia↓Fasting insulin↑HOMA-IR↓TC↓HDL−c↑ TG↓HbA1cJohnston KL **(**2010**)**UKRSPlacebo-controlstudyAdults with metabolic syndromeMF30.4 ± 1.15vs.31.3 ± 1.750.1 ± 4.05vs.45.2 ± 3.5520RS and RDS(40)RDS(0)12 weeks↓HOMA %S↓HOMA %B↓Insulin sensitivityBodinham CL (2012)UKRSCrossover studyOverweight individualsMF28.2 ± 0.437 ± 4.012RS and RDS(40)RDS(0)4 weeks↓Fasting glucose↑Fasting insulin↑Fasting TG⇿TCMaki KC (2012)USARSCrossover studyHealthy adultsMF30.6 ± 0.549.5 ± 1.633Corn starch containing60% RS(30)corn starch containing60% RS(15)Control starch containing no RS(0)control starch containing no RS(0)4 weeksMale:⇿Fasting glucose↓Fasting insulin⇿HOMA%B⇿HOMA%SFemale:⇿Fasting glucose↓Fasting insulin↓HOMA%B⇿HOMA%SMale:⇿Fasting glucose↓Fasting insulin↓HOMA%B⇿HOMA%SFemale:⇿Fasting glucose↓Fasting insulin↓HOMA%B⇿HOMA%SRobertson MD (2012)FranceRSCrossover studyHealthy subjects with insulin resistanceMF33.8 ± 1.948.9 ± 3.915RS and RDS(40)RDS(0)8 weeks↓Fasting glucose↓Fasting insulin↓HOMA-%B↓HOMA-IR↓Fasting TC↑Fasting TGGargari BP (2015)IranRSPlacebo-controlstudyAdults with type 2 diabetesF30.8 ± 5.2vs31.5 ± 4.549.6 ± 8.4vs49.5 ± 8.060RS2(10)Maltodextri-n(0)8 weeks↓Fasting plasma glucose↓TG↓TC↓HDL-c↓LDL-c↓HbA1cKarimi P (2015)IranRSPlacebo-controlstudyAdults with type 2 diabetesF31 ± 4.9vs31.5 ± 4.548.6 ± 7.9vs49.5 ± 8.056RS2(10)Maltodextri-n(0)8 weeks↓Fasting glucose↓Fasting insulin↓HOMA-IR↓HbA1cDainty SA (2016)CanadaRSCrossover studyAdults with risk of Type 2DiabetesMF30.2 ± 0.5755.3 ± 1.5924RS bagel(25)Control bagel(0)8 weeks↓Fasting plasma glucose↓Fasting serum insulin↓HOMA-IR↓HOMA%B↑HOMA%SBergeron N (2016)USARSCrossover studyMen and post-menopausal womenMF31 ± 244 ± 1452Higher-CHO study: RS(66)Lower-CHO study: RS(48)Higher-CHO study: RS(4)Lower-CHO study: RS(3)2 weeksHigher-CHO study:↓Fasting glucose↓Fasting insulin↓TC⇿TG⇿HDL-c⇿LDL-cLower-CHO study:↑Fasting glucose↑Fasting insulin⇿TC⇿TG⇿HDL-c⇿LDL-cGower BA (2016)USARSCrossover studyNondiabetic womenF29.8 ± 6.748.3 ± 12.623High-amyloseMaize(RS)(19.05)high-amyloseMaize(RS)(11.35)Control starch containing RS(3.18)control starch containing RS(3.18)4 weeksInsulin sensitive:↑Fasting glucose↑Fasting insulin↑TC↑TG⇿HDL-cInsulin resistance:↓Fasting glucose↓Fasting insulin↑TC↑TG↓HDL-cInsulin sensitive:⇿Fasting glucose↑Fasting insulin↑TC↓TG⇿HDL-cInsulin resistance:↓Fasting glucose↓Fasting insulin↓TC⇿TG⇿HDL-cSchioldan AG (2017)DenmarkRSCrossover studyParticipants with metabolic syndromeMF\>2558 ± 1119HCD: RS(21)WSD: RS(3)4 weeks⇿glucose↓insulin↓TG↓TC⇿HDL-c↓LDL-c↑HOMA-IRPeterson CM (2018)AmericanRSPlacebo-controlstudyAdults with prediabetesMF54 ± 10vs.55 ± 1035.5 ± 4.04vs.35.7 ± 5.259High-amylosemaize (RS)(45)Amioca cornstarch(0)12 weeks⇿fasting glucose↑fasting insulin↓TC↓TG↓HDL-c↓LDL-c↓HbA1c*BMI* body mass index, *M* male, *F* female, *RS* resistant starch, *RDS* rapidly digestible starch, *NBS* native banana starch, *IFG* impaired fasting glucose, *IGT* impaired glucose tolerance, *NSP* nonstarch polysaccharide, *CHO* carbohydrate, *WSD* refined carbohydrates, *HCD* healthy carbohydrate diet, *MID* mid-age adults, *ELD* elderly adults, *HbA1c* glycated hemoglobin*HOMA %S* fasted oral insulin sensitivity, assessed by homeostasis model assessment, *HOMA %B* b-cell function, assessed by homeostasis model assessment, *HOMA-IR* insulin resistance index, assessed by homeostatic model assessment, *TG* triglyceride, *TC* total cholesterol, *HDL-c* high density lipoprotein cholesterol, *LDL-c* low density lipoprotein cholesterol, *NR* not report⇿ no significant difference between the intervention and control groups after intervention↓ significantly lower than control group after intervention↑ significantly higher than control group after interventionTable 2Impact of consuming resistant starch versus placebo on glycemic status, insulin, and lipid profile at the end of studyStudy (year)Fasting glucose (momol/L) placebo vs. controlFasting insulin (mIU/L) placebo vs. controlHOMA %B placebo vs. controlHOMA %S placebo vs. controlHOMA-IR placebo vs. controlHbA1c (%) placebo vs. controlTC (mg/dL) placebo vs. controlTG (mg/dL) placebo vs. controlHDL-c (mg/dL) placebo vs. controlLDL-c (mg/dL) placebo vs. controlPark OJ (2004)5.33 ± 0.22vs.5.33 ± 0.3317.21 ± 4.95vs.33.57 ± 13.93NRNRNRNR123.74 ± 7.73vs.123.52 ± 7.73141.6 ± 56.64vs.127.44 ± 49.5633.64 ± 2.32vs.32.1 ± 2.32107.89 ± 5.41vs.110.6 ± 5.41Castillo JL (2010)8.0 ± 1.15vs.8.16 ± 0.4911.2 ± 1.4vs.13 ± 1.23NRNRNR6.3 ± 0.21vs.6.3 ± 0.25206 ± 8.13vs.207.5 ± 7.25252 ± 119.2vs.187 ± 2342.07 ± 1.5vs.44.07 ± 2.75NRJohnston KL (2010)NRNR162 ± 12.7vs.176 ± 24.280.2 ± 12.7vs.70.1 ± 5.68NRNRNRNRNRNRBodinham CL (2012)4.8 ± 0.1vs.5.1 ± 0.188.6 ± 9.5vs.85.4 ± 7.8NRNRNRNR185.62 ± 11.6vs.185.62 ± 11.6141.6 ± 26.55vs.115.05 ± 17.7NRNRMaki KC (2012)30 g RS:male1.8 ± 0.22vs.1.7 ± 0.1female5.4 ± 0.1vs.5.5 ± 0.115 g RS:male1.8 ± 0.8vs.1.7 ± 0.1female5.5 ± 0.1vs.5.5 ± 0.130 g RS:male58.5 ± 4.7vs.62.5 ± 4.7female47.5 ± 4.9vs.56.2 ± 4.915 g RS:male50.1 ± 4.7vs.62.5 ± 4.7female51.6 ± 5vs.56.2 ± 4.930 g RS:male70.3 ± 6.1vs.78.1 ± 6.1female80.7 ± 6.1vs.89.3 ± 6.115 g RS:male61.5 ± 6.1vs.78.1 ± 6.1female84.2 ± 6.2vs.89.3 ± 6.130 g RS:male4.6 ± 0.1vs.4.6 ± 0.1female4.7 ± 0.1vs.4.5 ± 0.115 g RS:male4.7 ± 0.1vs.4.6 ± 0.1female4.6 ± 0.1vs.4.5 ± 0.1NRNRNRNRNRNRRobertson MD (2012)5 ± 0.1vs.5.2 ± 0.11108 ± 8.4vs.129 ± 10.2175.9 ± 11.9vs.182.5 ± 12.6NR2.5 ± 0.2vs.2.9 ± 0.2NR162.41 ± 15.47vs.166.28 ± 11.6123.9 ± 17.7vs.106.5 ± 8.85NRNRGargari BP (2015)8.44 ± 2.02vs.8.67 ± 0.79NRNRNRNR7.7 ± 1.3vs.8.3 ± 1181.5 ± 39.1vs.203.1 ± 45.6146.5 ± 63.7vs.216.7 ± 59.845.2 ± 9.5vs.38.2 ± 7.1101.7 ± 40.8vs.119.1 ± 41.2Karimi Pv (2015)8.44 ± 2.02vs.8.86 ± 0.7969.86 ± 12.61vs.98.9 ± 32.7NRNR3.76 ± 1.7vs.5.6 ± 2.57.7 ± 1.15vs.8.5 ± 1.15NRNRNRNRDainty SA (2016)5.29 ± 0.075vs.5.31 ± 0.07568.7 ± 5.63vs.88.2 ± 7.08140 ± 18vs.170 ± 2239 ± 6vs.29 ± 42.57 ± 1.1vs.3.43 ± 1.3NRNRNRNRNRBergeron N (2016)66 g RS5.26 ± 0.55vs.5.3 ± 0.5548 g RS5.38 ± 0.51vs.5.27 ± 0.4966 g RS59.9 ± 31.34vs.67.56 ± 38.348 g RS61.29 ± 28.56vs.55.72 ± 27.16NRNRNRNR66 g RS166.28 ± 27.46168.21 ± 30.16 vs.48 g RS164.35 ± 24.36vs.164.73 ± 25.1466 g RS108.86 ± 38.06vs.109.74 ± 38.9448 g RS95.58 ± 45.14vs.100 ± 65.4966 g RS41.76 ± 6.57vs.42.92 ± 8.1248 g RS41.38 ± 8.12vs.41.76 ± 8.1266 g RS102.86 ± 18.56vs.103.25 ± 20.8848 g RS103.64 ± 19.34vs.104.02 ± 20.88Gower BA (2016)19.05 g RSinsulin sensitive:5.46 ± 0.72vs.5.56 ± 0.68insulin resistance5.46 ± 0.52vs.5.56 ± 0.6811.35 g RSInsulin sensitive:5.09 ± 0.47vs.4.88 ± 0.25Insulin resistance4.83 ± 0.37vs.4.88 ± 0.2519.05 g RSinsulin sensitive:66.86 ± 48.06vs.72.44 ± 32.04insulin resistance:68.26 ± 32.04vs.72.44 ± 32.0411.35 g RSinsulin sensitive:32.04 ± 8.36vs.27.86 ± 12.54Insulin resistance:32.74 ± 8.36vs.27.86 ± 12.54NRNRNRNR19.05 g RSinsulin sensitive:190.4 ± 37.4vs.187.6 ± 38.3insulin resistance:181.2 ± 24.4vs.187.6 ± 38.311.35 g RSinsulin sensitive:190.8 ± 41.9vs.179.6 ± 32.2insulin resistance:182.4 ± 34.4vs.179.6 ± 32.219.05 g RSinsulinsensitive:118.2 ± 59.1vs.117 ± 47.9insulinresistance:111.8 ± 59.1vs.117 ± 47.911.35 g RSinsulinsensitive:96.1 ± 31.1vs.83.7 ± 19.6insulinresistance:79.1 ± 27vs.83.7 ± 19.619.05 g RSinsulin sensitive:56.9 ± 14.3vs.59 ± 18insulin resistance:58.8 ± 9.6vs.59 ± 1811.35 g RSinsulin sensitive:62.9 ± 11.9vs.61.9 ± 8.1insulin resistance:62.7 ± 8.9vs.61.9 ± 8.1NRSchioldan AG (2017)5.9 ± 0.6vs.5.9 ± 0.673.1 ± 17.55vs.90.8 ± 14.3NRNR3.88 ± 0.6vs.3.61 ± 0.5NR176.34 ± 29.39vs.183.68 ± 33.64138.06 ± 21.46vs.139.83 ± 19.6939.44 ± 10.44vs.39.83 ± 9.67104.41 ± 28.62vs.110.21 ± 30.55Peterson CM (2018)6 ± 0.44vs.6.11 ± 0.4422.29 ± 5.4vs.21.29 ± 6.3NRNRNR5.7 ± 0.2vs.5.8 ± 0.2181.67 ± 29vs.184.67 ± 17.72108.25 ± 48vs.100.25 ± 25.6114.14 ± 12vs.110.14 ± 2445.9 ± 4.9vs.48.7 ± 4.08*RS* resistant starch, *HOMA %S* fasted oral insulin sensitivity, assessed by homeostasis model assessment, *HOMA %B* b-cell function, assessed by homeostasis model assessment, *HOMA-IR* insulin resistance index, assessed by homeostatic model assessment, *HbA1c* glycated hemoglobin, *TG* triglyceride, *TC* total cholesterol, *HDL-c* high-density lipoprotein cholesterol, *LDL-c* low-density lipoprotein cholesterol, *NR* not report

Quality assessment {#Sec11}
------------------

Twelve studies were rated as strong^[@CR15]--[@CR23],[@CR25]--[@CR27]^ and one study was as moderate^[@CR24]^ through the EPHPP method. All the studies were rated as strong according to the criteria "selection bias", "study design", "confounders", "withdrawals and dropouts", and "data collection methods", while one study^[@CR24]^ was evaluated as weak in the criteria of "blinding".

Overall and stratified analysis {#Sec12}
-------------------------------

We performed the meta-analyses on twelve studies^[@CR15],[@CR17]--[@CR27]^ for fasting glucose; ten trials^[@CR15],[@CR17]--[@CR19],[@CR21],[@CR23]--[@CR27]^ for fasting insulin; eight trials for total cholesterol^[@CR15],[@CR17],[@CR19],[@CR20],[@CR23]--[@CR25],[@CR27]^ and triglycerides^[@CR15],[@CR17],[@CR19],[@CR23]--[@CR27]^; four trials for HOMA-IR^[@CR15],[@CR21],[@CR22],[@CR24]^ and seven trials for HDL-c^[@CR15],[@CR20],[@CR23]--[@CR27]^; three trials^[@CR16],[@CR18],[@CR22]^ for HOMA-S% and HOMA-B%, and five trials for LDL-c^[@CR20],[@CR23]--[@CR26]^. Three studies^[@CR18],[@CR23],[@CR27]^, included two groups, respectively, in their analysis and this meta-analysis included all the groups. One data were removed from analysis of the insulin and total cholesterol respectively because of a heterogeneous source as was observed through inspecting of the forest plots and that does not affect the outcome of overall analysis.

The overall meta-analysis showed a significant decrease in the fasting glucose after RS consumption (SMD = --0.26; 95% CI: --0.5 to --0.02; *P* = 0.035) (Fig. [2](#Fig2){ref-type="fig"}); in the fasting insulin concentration (SMD = --0.72; 95% CI: --1.13 to --0.31; *P* = 0.001) (Fig. [3](#Fig3){ref-type="fig"}); in the LDL-c concentration (SMD = --0.35; 95% CI: --0.61 to --0.09; *P* = 0.008) (Fig. [5](#Fig5){ref-type="fig"}); in the HOMA-B% (SMD = --1.2; 95% CI: --1.64 to --0.77; *P* = 0.000) and in the HbA1c (SMD = --0.43; 95% CI: --0.74 to --0.13; *P* = 0.005), but there was a significant increase in the HOMA-S% (SMD = 1.19; 95% CI: 0.59--1.78; *P* = 0.000) (Fig. [4](#Fig4){ref-type="fig"}). Nonsignificant effect was showed in HDL-c; total cholesterol; triglycerides concentration, and HOMA-IR (SMD = 0.05; 95% CI: --0.27--0.38; *P* = 0.759; SMD = 0.21; 95% CI: --0.35--0.04; *P* = 0.113; SMD = 0.19; 95% CI: --0.18--0.56; *P* = 0.758 and SMD = --0.74; 95% CI: --1.61 to 0.14; *P* = 0.098; respectively) (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}).Fig. 2Forest plot for resistant starch and control groups in fasting glucoseFig. 3Forest plot for resistant starch and control groups in fasting insulinFig. 4Forest plot for resistant starch and control groups in HOMA-S%, HOMA-B%, HOMA-IR, and HbA1cFig. 5Forest plot for resistant starch and control groups in total cholesterol, LDL-c, HDL-c, and triglycerides

There was a significant decrease in the fasting insulin showed in the diabetic and nondiabetic subgroups (SMD = --1.26; 95% CI: --1.66 to --0.86; *P* = 0.000; SMD = --0.64; 95% CI: --1.10 to --0.18; *P* = 0.006, respectively) (Fig. [3](#Fig3){ref-type="fig"}). A significant decrease in fasting glucose was showed by studies with diabetics (SMD = --0.28; 95% CI: --0.54 to --0.01; *P* = 0.04) (Fig. [2](#Fig2){ref-type="fig"}). Both nondiabetic and diabetic subgroups indicated a non-significant effect in HDL-c; total cholesterol; and triglycerides concentration (Fig. [5](#Fig5){ref-type="fig"}).

There was significant heterogeneity in the analysis of fasting glucose, fasting insulin, HDL-c, triglycerides, HOMA-S%, HOMA-B%, and HOMA-IR (*I*^2^ = 57.1%, 80.6%, 58.7%, 71.3%, 71.6%, 53.8%, and 86%, respectively). The heterogeneity in the analysis for fasting glucose, fasting insulin due to the trials with nondiabetics (*I*^2^ = 66.2%, 80.7%, respectively). However, the heterogeneity for HDL-c and triglycerides due to the trial with diabetics and low study (*I*^2^ = 95.2%, 95.8%, respectively), we did not make stratified analysis for HOMA-S%, HOMA-B%, and HOMA-IR because of the few data.

Adverse effects {#Sec13}
---------------

Adverse effects after RS supplementation were reported in five studies, including flatulence^[@CR15],[@CR23],[@CR25]^, abdominal discomfort^[@CR18],[@CR23]--[@CR25]^, diarrhea and swelling^[@CR25]^, fullness^[@CR18],[@CR23],[@CR25]^, nausea, and constipation^[@CR18],[@CR25]^. Most of which were mild and disappeared after few days of consumption. Three studies^[@CR16],[@CR21],[@CR26]^ reported no adverse reaction after RS supplementation and five ones^[@CR17],[@CR19],[@CR20],[@CR22],[@CR27]^ did not report adverse effects as a result.

Publication bias {#Sec14}
----------------

Using the Egger weighted regression method, there was no publication bias found in analysis for fasting glucose (*P* = 0.445), fasting insulin (*P* = 0.245), total cholesterol (*P* = 0.182), HDL-c (*P* = 0.894), HOMA-S% (*P* = 0.476), HOMA-B% (*P* = 0.314), HOMA-IR (*P* = 0.573), LDL-c (*P* = 0.153), and triglycerides (*P* = 0.379).

Discussion {#Sec15}
==========

In this meta-analysis of 13 studies involving 428 subjects, we saw that RS had an increasing effect on HOMA-S% and a lowering effect on fasting glucose, fasting insulin, LDL-c concentration, HbA1c, and HOMA-B% were found in overweight or obese adults. In our study, there was no significant effect of RS supplementation on HDL-c, total cholesterol, triglycerides, and HOMA-IR, which was in line with another study^[@CR28]^. Meanwhile, the meta-analysis of the prebiotics showed that the inulin could reduce the total cholesterol, LDL-c and triglycerides concentrations in patients with hyperlipidemia^[@CR29]^.

In our study, there were 6--13 data for analysis of total cholesterol, HDL-c, LDL-c, and triglycerides. A mild decrease was showed in the trials for analysis of total cholesterol^[@CR15],[@CR19],[@CR20],[@CR23]--[@CR26]^, HDL-c^[@CR15],[@CR20],[@CR25],[@CR26]^, LDL-c^[@CR20],[@CR24]--[@CR26]^, and triglycerides^[@CR20],[@CR24],[@CR26]^. There was a mild increase showed in the trial for analysis of total cholesterol and triglycerides^[@CR27]^, and no significant difference after RS supplementation was found in the trials for analysis of total cholesterol^[@CR23]^, HDL-c^[@CR23],[@CR24],[@CR27]^, LDL-c^[@CR23]^, and triglycerides^[@CR23],[@CR24]^, which could explain the lack of significant impact in the analyses. Four of six data reported a slight decrease in the LDL-c as a result of significant effect in the nondiabetic subgroup and overall analyses of LDL-c. Meanwhile, a meta-analysis reported a significant reduce in total cholesterol and LDL-c after the prebiotics supplementation in overweight or obese adults^[@CR30]^. Previous studies have shown that different types of RS have opposite effects on glucose and lipid levels in healthy subjects and T2DM patients. The diversity of results may be due to differences in diet composition, dietary RS content, source of RS, dosage and type of RS, and the pathological status of the patients which can be a cause in significant heterogeneity in analysis. However, low-sample size may be the most likely reason.

Four studies were for analysis of HOMA-IR^[@CR19],[@CR21],[@CR22],[@CR24]^ and HOMA-B%^[@CR16],[@CR18],[@CR19],[@CR22]^, three for HOMA-S%^[@CR16],[@CR18],[@CR22]^. A mild decrease was showed in the data for analysis of HOMA-IR^[@CR19],[@CR21],[@CR24]^; HOMA-B%^[@CR16],[@CR18],[@CR19],[@CR22]^ and HOMA-S%^[@CR16]^. An increase^[@CR22]^ was showed for analysis of HOMA-S%, which can explain the effect in the overall analysis. Recent studies from animal models containing HAM-RS2 have shown an increase in pancreatic beta cell^[@CR31]^. SCFA, especially acetate and propionate produced by colonic fermentation of colonic bacteria, have also been associated with the insulin sensitized effects of RS^[@CR18],[@CR32]^. Another mechanism associated with insulin sensitivity is to regulate systemic inflammation by altering both gut microbiota and intestinal permeability.^[@CR33]^. In this meta-analysis of HOMA-S%, one trial^[@CR9]^ showed the effect on inflammatory marker (hs-CRP) was not significantly changed by RS. Low-sample size and nondiabetic, including metabolic syndrome may be a cause in significant heterogeneity in analysis.

Although there were 144 diabetics in the included trials^[@CR15],[@CR20],[@CR21]^, mean fasting insulin and glucose concentration at the baseline were 12.16 mIU/L and 6.98 mmol/l (diabetic: 8.31 mmol/l; nondiabetic: 6.06 mmol/l), respectively. A mild decrease was showed in the trials for analysis of fasting glucose^[@CR15],[@CR17],[@CR19],[@CR20],[@CR22],[@CR23],[@CR25],[@CR27]^ and fasting insulin^[@CR15],[@CR18],[@CR19],[@CR21]--[@CR23],[@CR25],[@CR27]^. No significant difference was found in the trials for analysis of fasting glucose^[@CR18],[@CR24],[@CR26]^ and four data showed an increase in fasting insulin^[@CR17],[@CR23],[@CR26],[@CR27]^ and two in fasting glucose^[@CR23],[@CR27]^, which may have prevented a significant effect on analysis of glucose with nondiabetic. Colonic fermentation of HAM-RS2 increases acetate and propionate concentration^[@CR32]^. In our study, one trial^[@CR18]^ showed the difference of SCFA after RS supplementation, however, there was no significance. Circulating SCFA, especially propionate, may also increase insulin secretion by binding to PPAR-γ receptors in adipose tissue^[@CR32]^. The mechanism by which RS may decrease the fasting glucose has been investigated by many experimental studies, but it is considerable ambiguity. A study has shown that RS meets prebiotic criteria and can stimulate an increase of endogenous *Bifidobacteria*^[@CR34]^. The increase in Clostridium cluster IV was negatively associated with fasting insulin and glucose, while a positive correlation between Propionibacterium, Bacteroides intestinalis, Bacteroides vulgates, and fasting glucose was found in another study^[@CR35]^.

Some limitations of our study should be taken into consideration. First, we excluded some trials which did not provide baseline characteristic without difference. The plasma glucose and insulin were calculated as the positive area under the curve, thus, we excluded those studies for further analysis, which may influence the accuracy of the overall results. Second, in some meta-analyses, the number of studies is relatively limited, which may cause problems for evaluation of heterogeneities and publication bias and finally reduce the confidence of the results. Third, our study did not include the subjects with BMI \<25, and establish the subgroup analysis according to the dosage and duration of RS. Fourth, there is a significant heterogeneity and possible publication bias in our study. Although there was no publication bias found for all the analysis, significant heterogeneity was found in fasting glucose, fasting insulin, HDL-c, HOMA-S%, HOMA-B%, and HOMA-IR, and this heterogeneity remained significant for analysis of trials with nondiabetic which depended on different countries, RS types, duration of treatment, and other unforeseen factors. Finally, the dietary intake may vary within and between individuals, which may lead to changes in insulin, glucose homeostasis, and lipid. Another important issue to consider is the composition of intestinal microflora, which is the main goal of metabolic improvement.

Conclusion {#Sec16}
==========

In summary, this meta-analysis showed that RS increased HOMA-S% and reduced fasting insulin, fasting glucose, LDL-c concentration, HbA1c, and HOMA-B%, in overweight or obese adult, and they also decreased fasting glucose and HOMA-IR in overweight or obese adult with diabete. However, due to potential confounding, individual variations and gut microbiota composition, this result should be carefully considered and be confirmed by further study.
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